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1. Introduction 
The recent advances in pancreatic imaging lead to higher detection of pancreatic cysts [1]. It 
has become very common for general practitioners as well as gastroenterologists to face the 
dilemma of further management of a large number of incidentally found pancreatic cysts. In 
this chapter, we will discuss the epidemiology, pathogenesis and the role of EUS in 
managing pancreatic cysts. 
2. Epidemiology 
The prevalence of pancreatic cysts is much higher than previously estimated. Earlier reports 
suggested that the prevalence of pancreatic cysts in adult populations to be around 2.5% [2] . 
Recent studies using Magnetic Resonance Imaging (MRI) showed a higher prevalence of 
pancreatic cysts in the general population up to 13%  [3]. This prevalence increases with age 
and for an unknown reason it is extremely high (more than 50%) in liver transplanted 
patients [4].  
3. Pathology 
Pancreatic cysts can be classified according to their malignant potential or according to their 
morphological features. Initially, pancreatic cyst could be classified as pseudocyst which 
indicates the lack of the epithelial lining of the cyst wall, true cyst with epithelial lining or 
cystic degeneration or necrosis of solid pancreatic masses [5]. Pseudocyst are common after 
acute or chronic pancreatitis as a result of extravasation of pancreatic fluid from the 
disrupted pancreatic duct [6]. Pseudocyst complicating acute pancreatitis has no malignant 
potential and the majority of them will resolve spontaneously [7]. The management of 
pseudocyst is beyond the scope of this review.  
True pancreatic cysts can be further divided into cysts lined with mucinous epithelium 
(mucinous cystic neoplasms and Intraductal Papillary Mucinous Neoplasm [IPMN]), cysts 
lined with clear cell (serous cystic tumors) or cysts lined with acinar cells. In addition, cystic 
degeneration of solid tumor can occur such as cystic neuroendocrine tumors and 
pseudopapillary tumors [8]. 
The hallmark of mucinous cystic neoplasms (mucinous cystadenoma) of the pancreas is the 
presence of ovarian stroma [9]. More than 90% of patients with mucinous cystic neoplasms 
are females and more than 90% of these lesions are within the body - tail region of the 
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pancreas [10]. Macroscopically, mucinous cysts are large and multilocular with thick wall. 
Mucinous cystic neoplasms usually do not communicate with the pancreatic duct. Ten to 
15% of the discovered mucinous cystic neoplasms were found to have invasive carcinoma or 
at least carcinoma in situ [11, 12].  
Unlike mucinous cystic neoplasms, IPMN arises within the pancreatic duct and it is 
characterized by papillary projections containing neoplastic mucin producing cells [13]. 
Macroscopically, IPMN appears as cystic dilations of the pancreatic duct. Cysts are varying 
in size and they are filled with mucin. Occasionally mucin could be seen extruding from the 
ampulla which is virtually pathognomonic for IPMN. IPMN can be divided according to its 
anatomical location as main duct - branch duct- and mixed-IPMN. The histological 
classification divides IPMN into four main categories: gastric, intestinal, pancreatobiliary 
and oncocytic type [14]. Both classifications are very important in determining the 
malignant potential of the disease. For example, the malignant potential of main duct - and 
of intestinal type of IPMN is much higher than branch duct IPMN and gastric type IPMN 
[15]. IPMNs are equally distributed between males and females and their incidence 
increases with age [16]. In a retrospective trial of  208 patients who underwent pancreatic 
resection of IPMN, 64 % of main duct IPMN were malignant while only 18 % of branch duct 
IPMN were harboring malignant cell on pathological examination [17]. 
Serous cystic tumors of the pancreas are lined by glycogen rich cell secreting serous fluid 
[18]. Macroscopically, it has sponge appearance with large number of minute cysts with 
occasional central scar. Usually serous cysts are large in size with a diameter of several 
centimeters. Serous cystic tumors are more common in females over 60 years old [19] with 
rare malignant potential (~3%) [20, 21]. 
The cystic form of acinar cell tumor is rare [22]. It could be present in a benign form as 
acinar cell cystadenoma, in addition to the malignant form known as acinar cell 
cystadenocarcinoma [23, 24]. This rare tumor entity should not be confused with solid 
pseudopapillary tumor of the pancreas in which the cystic component is rather a 
degenerative process than true cyst as in the cystic form of acinar cell tumors [25]. Both 
tumors, however, occur in young patients and should be included in the differential 
diagnosis in cystic tumor of the pancreas in pediatric and young adults. The cystic form of 
neuroendocrine tumor is another example of cystic degeneration within solid tumor. There 
are few case reports describing cystic glucagonoma and cystic insulinoma in the literature 
[26, 27]. The cyst is usually filled with clear fluid secreted by the neuroendocrine cells and 
not necrotic materials as in the case of solid pseudopapillary tumor[5]. It is also worth 
mentioning that cystic degeneration can occur in any solid tumor of the pancreas including 
ductal adenocarcinoma. 
4. Role of imaging in diagnosing pancreatic cystic lesions 
Although the advances in diagnostic imaging allowed more discovery of incidental 
pancreatic cyst, CT scan has only 50 to 60% accuracy in differentiating between different 
types of pancreatic cysts [28]. The new generation multi-slice helical CT scan has higher 
accuracy in differentiating between serous and mucinous cysts with a diagnostic accuracy of 
70 to 80% [29]. The accuracy of a CT scan is not that impressive either in differentiating 
benign from malignant cysts. In a study of 47 patients with IPMN who underwent surgical 
resection, the diagnostic accuracy of a CT scan in differentiating invasive from non-invasive 
cyst was 76% [30]. Magnetic Resonance Imaging (MRI) of the pancreas could have better 
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diagnostic performance in differentiating mucinous from non-mucinous cysts  in 
comparison with the CT scan[31]. In addition, MRI enables more characterization of cyst 
features suggestive of malignancy such as mural nodule, thick septae, solid component or 
main pancreatic duct dilation [32, 33]. However, studies comparing the relative accuracy of 
MRI and CT scan in differentiating benign from malignant cysts did not show any 
difference between the two modalities. In a retrospective study of 58 pancreatic cystic 
lesions irrespective of the cyst size, the relative accuracy of CT and MRI was similar  [34]. In 
another well-designed retrospective trial by Sainani et al, 38 small (less than 3 cm) 
pancreatic cysts were included. All patients had a CT scan, MRI and histopathological 
diagnosis. CT and MRI had overall similar performance. The accuracy of CT scan and MRI 
in differentiating mucinous from non-mucinous cyst was 71% and 84% respectively, while 
the accuracy of CT vs MRI in differentiating benign from malignant cyst was 75-78% vs 78-
86% (not statistically significant) [35]. Recently, 3D MRCP was shown to improve the image 
quality of pancreatic cysts [36]. However, 3D MRCP had similar diagnostic performance to 
2D MRCP in differentiating benign from malignant cysts [37]. 
5. Role of Endoscopic Ultrasonography (EUS) 
5.1 Cyst morphology 
EUS has emerged as an important tool in the diagnosis of pancreatic cysts. EUS allows close 
inspection of pancreatic cysts and delineates the characteristic features of the cyst that might 
not be apparent on CT or MRI. For example, serous cystadenoma (SCA) has a typical 
honeycomb appearance with multiple microcysts separated with thin septae and 
occasionally central scar [38]. Mucinous cystadenoma (MCA) is usually present in the body 
and tail of the pancreas as a well-circumscribed, rounded, anechoic cyst without any 
communication with the pancreatic duct. Branch duct IPMN has a similar appearance to 
MCA but it is not rounded, occasionally multicystic with communication with the 
pancreatic duct [39]. In some occasions, MCA cannot be differentiated from branch duct 
IPMN if the communication with the pancreatic duct is not clear.  Main duct IPMN appears 
as a cystic dilation of the main pancreatic duct and it could be either segmental or diffuse in 
nature. EUS can also identify features that are worrisome for malignancy such as solid 
component, thick septae or lymphadenopathy [40, 41]. However, EUS alone cannot 
differentiate benign from malignant cysts [42]. In a retrospective study of 47 patients who 
underwent EUS examination prior to surgical resection of the pancreatic cyst, the diagnostic 
accuracy of EUS to differentiate benign from malignant cyst was 76% [30]. Furthermore, 
interobserver agreement among endosonographers to differentiate mucinous from non 
mucinous cysts was evaluated by Ahmad et al. by using videotapes of 31 pancreatic cystic 
lesions. The interobserver agreement among the eight endosonographers included in the 
study was shown to be only fair (kappa =0.24). Accuracy rates of EUS to differentiate benign 
from malignant lesions ranged from 40 to 93% which highlights the variability among 
endosonographers [43]. The result of this study should be taken with a grain of salt since the 
endosonographers were evaluating video tapes which are different than performing the 
actual procedure and interpreting the findings. 
5.2 Cytological evaluation 
In addition to cyst characterization, EUS allows fine needle aspiration (FNA) of the cyst 
for cytology and measurement of molecular markers. FNA of pancreatic cyst is safe with 
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complication rate of 0.5 to 2% as acute pancreatitis, bleeding or infection [44-47]. Although 
cytology of pancreatic cyst has high specificity, its sensitivity is very low in differentiating 
mucinous from non-mucinous cysts. Sedlack et al in a retrospective study of 111 patients 
at Mayo Clinic found that cytology had 100% specificity and 27% sensitivity for mucinous 
cysts. This translates into 55% diagnostic accuracy [40]. Similar results were confirmed by 
Attasaranya et al from Indiana University in a retrospective study of 48 patients with 
pancreatic cysts. The specificity of cytology to differentiate mucinous from non-mucinous 
cyst was 90% with sensitivity of 12.5% [48]. What can explain such high specificity and 
low sensitivity for cytology is that the presence of sticky fluid on aspiration or mucin in 
cytology is highly diagnostic for mucinous cysts. However, aspirate can be acellular or 
with minimal cellularity in up to 72% of aspirated cysts [49, 50].  FNA is not useful in SCA 
with diagnostic accuracy of only 17% [51]. Giving the innumerable microcystic structure 
of SCA, FNA is often non diagnostic due to the lack of fluid aspirate. However, the 
presence of glycogen rich cells is highly specific for SCA [51, 52]. In terms of 
differentiating benign from malignant cyst, cytology has an accuracy of 50% in most of the 
trials reported in the literature [53-56]. The presence of tight epithelial cell clusters with 
hyperchromic cell nuclei and high nuclei to cytoplasm ratio is suggestive of malignant 
cysts [50, 57]. Giving the higher risk of bacteremia in FNA of cystic lesions of GI tract in 
comparison with solid lesions, the American Society of Gastrointestinal Endoscopy 
(ASGE) recommends antibiotics administration prior to FNA of cystic lesions of the 
pancreas [58]. 
Recently, a new through the needle cytology brush system (Echobrush, Cook Endoscopy, 
Winston-Salem, NC) was developed in order to improve the diagnostic accuracy of the 
FNA. This system was initially evaluated at Mayo Clinic Florida in a pilot study of 10 
patients with pancreatic cysts who prospectively underwent standard FNA followed by 
FNA with Echobrush. Echobrush was superior to the standard FNA in 7 of the 10 patients. 
However, two of the 10 patients (who stopped anticoagulation 5 days prior to the 
procedure) had bleeding complication after the procedure; in one patient the bleeding 
stopped on its own, while angiographic embolization was required to stop the bleeding in 
the 2nd patient [59]. Similar findings were replicated by Bruno et al in cases series of 39 
patients with 12 pancreatic cysts. Six of 12 patients with pancreatic cysts had an adequate 
cellularity sample with only 1 Echobrush pass [60].  In a larger study by the same group at 
Mayo Clinic Florida, Echobrush was more likely to detect intracellular mucin on cytology 
specimen compared to EUS-FNA in 39 pancreatic cysts larger than 2 cm. However, two 
patients developed acute pancreatitis and one patients developed post brushing acute 
bleeding [61].   
Sendino et al from Spain reported an increased accuracy of Echobrush compared to 
conventional FNA in a group of 22 patients with pancreatic cystic neoplasms (cellular 
diagnosis in 91%). However, the authors witnessed complications of this procedure in 3 
patients (10%) which included a subacute retroperitoneal haemorrhage in a patient on 
anticoagulation who died one month after the procedure [62]. The most recent study by 
Thomas et al from United Kingdom did not show any difference in the cytology yield 
between Echobrush and the standard FNA in prospective study of 51 patients [63]. In 
conclusion, more studies are needed to evaluate the efficacy and the safety of the new 
Echobrush system prior to recommending it for routine clinical practice. To date, Echobrush 
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5.3 Molecular markers 
The measurement of intracystic markers and in particular of Carcinoembryonic Antigen 
(CEA) has emerged as an additional tool in evaluating pancreatic cysts. In a landmark 
prospective study published in 2004 by the cooperative pancreatic cyst study, 341 patients 
with pancreatic cysts underwent FNA. The utility of CEA, CA 72-4, CA 125, CA 19-9, and 
CA 15-3 in differentiating mucinous from non-mucinous cyst was evaluated. Only CEA was 
proven to be valuable in differentiating mucinous from non-mucinous cyst. The study 
suggests that an intracystic CEA level higher than 192 ng/ml can predict the presence of 
mucinous cyst with diagnostic accuracy of 79% which was higher compared to EUS 
morphology alone (accuracy 51%)  and cytology (accuracy 59%)  (p:<0.05) [64]. In a 
retrospective study of 126 patients with proven pathological diagnosis of pancreatic cyst, 
CEA level of 200 ng/ml had a sensitivity of 60%, specificity of 93% and diagnostic accuracy 
of 72% in differentiating mucinous from non-mucinous cyst [65]. Although CEA was proven 
useful in differentiating mucinous from non-mucinous pancreatic cysts, the CEA utility in 
differentiating benign from malignant cysts is questionable. A pooled analysis of 12 trials 
proposed that a CEA level of 800 ng/ml can differentiate benign from malignant cyst (48% 
sensitive and 98% specificity) [53]. Another trial suggested that a CEA level of 6000 ng/ml 
can differentiate benign from malignant cyst [66]. However, many trials did not find CEA 
useful in differentiating benign from malignant cysts [65]. In a retrospective long-term 
follow-up study (median follow up period is 21 months) of 267 patients with pancreatic 
cysts, Nagula et al found that intracystic CEA level had no correlation with malignant 
changes of the cyst or with the cyst progression in size [67]. The above mentioned data 
indicate that intracystic CEA level should be limited to differentiation between mucinous 
and non-mucinous cyst.  
Cyst amylase level is usually elevated in pseudocyst and IPMN, given the communication of 
these cysts with the pancreatic duct [66]. Interestingly, malignant IPMN cyst was found to 
have a higher amylase level compared to benign IPMN cysts [65]. 
Identifying DNA mutations in the cysts by genetic markers is considered the new frontier in 
differentiating benign from malignant pancreatic cysts. Several mutations were found to be 
associated with progression of pancreatic cysts from non-dysplastic to dysplastic cysts such 
as k-ras, p-16 and p53 mutations [68-70]. Currently, it is commercially available to measure 
k-ras point mutations and loss of heterozygosity (LOH) analysis of tumor suppressor gene 
[71]. The PANDA study, which is a landmark study in the area of the utility of DNA 
markers in evaluating pancreatic cyst, prospectively enrolled 113 patients with pancreatic 
cysts and proven pathology. Elevated cyst DNA content and k-ras mutation were associated 
with malignant cyst. The presence of k-ras mutation in this study had high specificity of 
96%, but low sensitivity of 37% in diagnosing malignant cysts [72]. k-ras mutation correlated 
with atypical cytology and a high CEA level in a study of 60 patients with pancreatic cysts 
measuring less than 3 cm in size and without mural nodule or pancreatic duct dilation [73]. 
The above results are dissimilar with another trial of 27 patients who underwent EUS with 
FNA and measurement of CEA level, k-ras mutation and LOH mutation. In this trial, 
correlation between histology, CEA level, k-ras mutation and LOH mutation occurred in 
35% of cases, all of which were benign cases. In addition, the sensitivity of k-ras and LOH 
mutation to detect malignant cysts was significantly low compared to CEA (33% and 50% vs 
66%, respectively). Given the high specificity of k-ras mutation to detect malignant cyst 
(92%), the authors of the study recommended ordering DNA mutation analysis only in 
patients with equivocal results or when malignancy is suspected [74].  
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6. Role of EUS in pancreatic cyst ablation 
EUS has emerged from being a merely diagnostic utility to be an effective therapeutic utility 
in various gastrointestinal disorders. Management of pancreatic cyst is an example of this 
transformation. In addition to the important role of EUS in diagnosing pancreatic cysts, new 
studies are currently evaluating the role of EUS in pancreatic cyst ablation with the use of 
different agents. Ethanol lavage of the pancreatic cyst was successful in ablating 35% of 
included cysts in a small study of 25 patients [75]. A randomized controlled trial of 58 
patients compared ethanol lavage to saline lavage for cyst ablation found that ethanol 
lavage was more effective in decreasing cyst diameter compared to saline lavage. Thirty-
three patients from both arms of the study underwent a second ethanol lavage with 
complete cyst resolution in 12 patients (33.3%). Ethanol lavage was generally safe with a 5% 
rate of acute pancreatitis. Twenty-two per cent of patients who underwent ethanol lavage 
complained of mild abdominal pain after the procedure [76]. In a long-term follow-up study 
of the same 12 patients who had complete cyst resolution, follow-up CT scan was available 
in 9 patients. No cyst recurrence was seen in the mean follow-up period of 26 months [77]. A 
combination of ethanol and Paclitaxel was used in a recent prospective trial of 52 patients. 
Paclitaxel is a chemotherapeutic agent which can prevent cyst growth in the long-term 
without leakage from the cystic space. 62% of patients enrolled in this trial had complete 
cyst resolution. The procedure was generally safe with 1 case of mild pancreatitis and 1 case 
of splenic vein obliteration reported [78].  Critiques of this study include the questionable 
injection of chemotherapeutic agent in a cyst most likely benign in nature.  
More studies are needed to evaluate the long-term efficacy of these new technique and to 
define which types of cysts are more responsive to cyst ablation. It is also worth mentioning 
that the majority of cysts included in these studies are either mucinous or serous cysts. Cyst 
with communication with the pancreatic duct such as IPMN cannot be ablated because of 
the risk of inducing stricturing of the pancreatic duct. 
7. Role of EUS in surveillance of pancreatic cysts 
In addition to the role of EUS in establishing the diagnosis of pancreatic cyst , EUS is a 
useful tool in surveillance of  patients with cysts of unclear malignant potential. This role is 
particularly important in side branch IPMN in which disease progression could vary from 
patient to another. There is abundant evidence now that smaller side branch IPMN cysts are 
usually benign and that malignant potential of these cysts is correlating with its size [79]. 
Three cm in size was proposed as a cut off value in differentiating benign from potentially 
malignant branch duct IPMN. Branched ducts IPMN less than 3 cm in size and without any 
mural nodule are usually benign [80]. Surveillance EUS can monitor those patients with 
branch duct IPMN for size progression or for development of worrisome features such as 
mural nodule or mass component and accurately refer them to surgery. It is also worth 
mentioning that symptomatic side branch IPMN should be referred to surgery regardless of 
its size [81]. Guidelines also advocate referring all patients with MCA and main duct IPMN 
to surgery, if they are surgically fit. [82, 83] 
8. Integrating EUS in clinical practice 
EUS should be used in the context of the clinical data and its result should not be interpreted 
in isolation of other finding. For example, an isolated cyst in the tail of the pancreas in a 
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middle age female is most likely mucinous cystadenoma rather than branch duct IPMN. The 
same principle applies to interpreting FNA and cytology results.  FNA has low yield in a 
cyst smaller than 1 cm without any worrisome features. Also, if the patient is not a surgical 
candidate either because of multiple comorbidities or advanced age, FNA cannot be justified 
[84]. For this reason the decision for FNA should be taken on case by case basis. Negative or 
non diagnostic cytology of suspicious pancreatic cyst should not deter the clinician from 
considering surgery of the cystic lesion especially if the cyst has features of malignancy. In 
29 patients with pancreatic cystic lesions who underwent EUS FNA prior to surgical 
resection, more than 2/3 of cysts with negative cytology and 90% of cysts with non 
diagnostic cytology were harboring malignant or premalignant tissue on surgical specimens 
[85].  
9. Conclusions 
The role of EUS in the management of pancreatic cyst is crucial. However, EUS results 
should be incorporated in the overall clinical assessment of the patients. 
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As result of progress, endoscopy has became more complex, using more sophisticated devices and has
claimed a special form. In this moment, the gastroenterologist performing endoscopy has to be an expert in
macroscopic view of the lesions in the gut, with good skills for using standard endoscopes, with good
experience in ultrasound (for performing endoscopic ultrasound), with pathology experience for confocal
examination. It is compulsory to get experience and to have patience and attention for the follow-up of
thousands of images transmitted during capsule endoscopy or to have knowledge in physics necessary for
autofluorescence imaging endoscopy. Therefore, the idea of an endoscopist has changed. Examinations
mentioned need a special formation, a superior level of instruction, accessible to those who have already
gained enough experience in basic diagnostic endoscopy. This is the reason for what these new issues of
endoscopy are presented in this book of New techniques in Gastrointestinal Endoscopy.
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